-
1.发明公开KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF 审中-公开KINASEMODULIERENDE化合物，组合物和正确使用
公开(公告)号：EP2780341A1
公开(公告)日：2014-09-24
申请号：EP12849393.9
申请日：2012-11-14
发明人： XIAO, Dengming , LI, Jijun , ZHU, Yan , HU, Yuandong , WANG, Huting , WANG, Zhe , WANG, Zanping , WEI, Yongheng , SUN, Yinghui , WU, Qiong , ZHANG, Hui , PENG, Yong , KONG, Fansheng , SUN, Ying , LUO, Hong , HAN, Yongxin
IPC分类号： C07D473/00 , C07D401/04 , A61K31/52 , A61P35/00
CPC分类号： C07D473/00 , C07D487/04
摘要： The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
-
公开(公告)号：EP3050880B1
公开(公告)日：2019-06-19
申请号：EP14849754.8
申请日：2014-09-28
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XIAO, Dengming , ZHU, Yan , HU, Yuandong , WANG, Huting , LI, Jijun , PENG, Yong , ZHANG, Hui , LUO, Hong , KONG, Fansheng , HAN, Yongxin
IPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00
-
公开(公告)号：EP3330258A1
公开(公告)日：2018-06-06
申请号：EP16829878.4
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHAO, Na , WANG, Shulong , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Xiquan , XU, Hongjiang
IPC分类号： C07D251/18 , C07D251/26 , A61K31/53 , A61P35/00
CPC分类号： A61K31/53 , C07D251/18 , C07D251/26
摘要： Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
-
公开(公告)号：EP3235819A1
公开(公告)日：2017-10-25
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
摘要翻译： 本申请涉及药物化学领域，特别涉及通式（I）所示的吡咯并嘧啶化合物，其立体异构体或其药学上可接受的盐。 本发明还涉及通式（I）代表的吡咯并嘧啶化合物的制备方法，药物组合物和吡咯并嘧啶化合物在治疗由Janus激酶介导的疾病中的用途。
-
公开(公告)号：EP3330263B1
公开(公告)日：2020-11-18
申请号：EP16829888.3
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin
IPC分类号： C07D333/24 , C07D409/12 , C07D213/56 , C07D231/12 , C07D409/10 , C07D333/20 , C07C275/42 , A61K31/17 , A61K31/38 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4418 , A61K31/4436 , A61K31/4535 , A61P35/02
-
6.发明公开
公开(公告)号：EP3533796A1
公开(公告)日：2019-09-04
申请号：EP17863410.1
申请日：2017-10-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , HU, Yuandong , WU, Wei , DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , SUN, Yinghui , HAN, Yongxin , PENG, Yong , KONG, Fansheng , LUO, Hong , YANG, Ling , XU, Hongjiang , GUO, Meng , ZHONG, Zhaobai , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
-
公开(公告)号：EP2780341B1
公开(公告)日：2019-02-13
申请号：EP12849393.9
申请日：2012-11-14
发明人： XIAO, Dengming , LI, Jijun , ZHU, Yan , HU, Yuandong , WANG, Huting , WANG, Zhe , WANG, Zanping , WEI, Yongheng , SUN, Yinghui , WU, Qiong , ZHANG, Hui , PENG, Yong , KONG, Fansheng , SUN, Ying , LUO, Hong , HAN, Yongxin
IPC分类号： C07D473/00 , C07D487/04 , A61K31/52 , A61P35/00 , A61K31/519 , A61P25/00 , A61P29/00 , A61P37/00
-
公开(公告)号：EP3141546A1
公开(公告)日：2017-03-15
申请号：EP15789528.5
申请日：2015-05-07
发明人： HAN, Yongxin , ZHU, Li , XIAO, Dengming , PENG, Yong , LUO, Hong
IPC分类号： C07D401/04 , C07D403/04 , C07D231/38 , A61K31/454 , A61K31/5377 , A61K31/415 , A61P37/02 , A61P29/00 , A61P11/06 , A61P19/02 , A61P19/04 , A61P35/00 , A61P35/02
CPC分类号： C07D401/04 , A61K31/415 , A61K31/454 , A61K31/5377 , C07D231/38 , C07D403/04
摘要： Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.
摘要翻译： 提供由式（III）表示的化合物或其药学上可接受的盐，溶剂合物，活性代谢物，多晶型物，酯，互变异构体或前药，含有由式（III）表示的化合物的药物组合物，以及药物组合物作为选择性的应用 Bruton酪氨酸激酶的不可逆抑制剂用于预防和治疗与异常B细胞增殖和癌症相关的炎症，自身免疫性疾病（如类风湿性关节炎）。
-
公开(公告)号：EP2925740A1
公开(公告)日：2015-10-07
申请号：EP13858966.8
申请日：2013-11-29
发明人： HAN, Yongxin , YU, Rong , WANG, Zanping , LIANG, Zhi , HU, Quan , ZHU, Li , HU, Yuandong , SUN, Yinghui , ZHAO, Na , PENG, Yong , ZHAI, Xiaofeng , LUO, Hong , XIAO, Dengming
IPC分类号： C07D401/04 , C07D403/04 , C07D231/38 , A61K31/454 , A61K31/4155 , A61K31/415 , A61K31/5377 , A61K31/496 , A61P37/02 , A61P29/00 , A61P11/06 , A61P19/02 , A61P19/04 , A61P35/00 , A61P35/02
CPC分类号： C07D403/04 , C07D231/38 , C07D401/04
摘要： The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)
摘要翻译： 本发明提供由式（IV）表示的新型多取代5-元杂环化合物或其药学上可接受的盐，溶剂化物，代谢物，多晶型物，酯，互变异构体或前药以及包含这些化合物的组合物。 所提供的化合物可以用作选择性不可逆布鲁顿氏酪氨酸激酶（Btk）抑制剂，并且还可用于治疗与异常B细胞增殖有关的炎性自身免疫疾病，例如RA（类风湿性关节炎）和癌症。 本发明还提供了使用式（IV）的药物的制备方法，以及在哺乳动物特别是人类中预防或治疗与过量的Btk活性有关的疾病的方法。 式（IV）
-
10.发明公开
公开(公告)号：EP3434676A1
公开(公告)日：2019-01-30
申请号：EP17769492.4
申请日：2017-03-27
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
摘要： The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.021 秒)
